Clinical trials
Relapsed or Refractory Acute Myeloid Leukemia (AML) clinical trials
Below are recruiting relapsed or refractory acute myeloid leukemia (aml) clinical trials, each written for real people, not researchers. We’re tracking 1,381 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07082803RecruitingPhase 1
TLN-121 for relapsed or refractory non-Hodgkin lymphomas
This trial tests a new drug called TLN-121 for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if the drug is safe and effective.
Palo Alto, CaliforniaAges 18 years+ - NCT04879043RecruitingPhase 1/Phase 2
Safety study of HDP-101 for relapsed myeloma patients
This early-phase trial tests whether HDP-101 is safe and can potentially help adults with multiple myeloma that has come back or didn’t respond to standard treatments. It focuses on people who have already tried key myeloma medicines and still have measurable disease.
Atlanta, GeorgiaAges 18 years+ - NCT06565689RecruitingPhase 1
YK012 for B-cell non-Hodgkin lymphoma after prior treatments
This study tests a new daily pill called YK012 for people with certain types of B-cell non-Hodgkin lymphoma that have not responded to at least two prior treatments. The goal is to see if it is safe and if it can shrink tumors.
Beijing, Beijing MunicipalityAges 18–65 - NCT06121843RecruitingPhase 1
Study of CAR-T cell therapy in combinations for multiple myeloma
This trial tests a new CAR-T cell therapy (called arlocabtagene autoleucel) combined with other drugs for multiple myeloma that has returned or stopped responding. It aims to find a safe and effective dose while tracking how well the treatment works.
Birmingham, AlabamaAges 18 years+ - NCT04301076RecruitingPhase 1
Testing lenalidomide with EPOCH for adult T-cell leukemia-lymphoma
This trial tests whether adding lenalidomide to a standard chemotherapy regimen (EPOCH) helps people with adult T-cell leukemia-lymphoma (ATLL). It aims to improve how well the treatment works.
Atlanta, GeorgiaAges 18 years+ - NCT03494296Recruiting
Low-dose decitabine plus COP for relapsed lymphoma
This trial studies whether a low-dose chemotherapy medicine (decitabine) combined with a COP chemotherapy regimen can help adults whose diffuse large B-cell lymphoma (DLBCL) has come back or did not respond to treatment. It may be an option if you have measurable disease and can meet key safety and health requirements.
Harbin, HeilongjiangAges 18 years+ - NCT03509961RecruitingPhase 2
Reducing total body radiation for children with leukemia transplants
This study looks at whether some children and young adults with B-ALL can safely get a transplant without total body irradiation (TBI), based on special leukemia test results. It’s meant to help lower radiation-related risks while keeping leukemia control strong.
Birmingham, AlabamaAges 1–25 - NCT03681561RecruitingPhase 1/Phase 2
Nivolumab plus ruxolitinib for relapsed Hodgkin lymphoma
This trial tests nivolumab (an immune therapy) combined with ruxolitinib (a drug that targets immune signaling) for people whose classical Hodgkin lymphoma has come back or did not respond. It may help shrink the lymphoma and improve disease control after prior treatments, including checkpoint inhibitor therapy.
Chicago, IllinoisAges 18 years+ - NCT03761108RecruitingPhase 1/Phase 2
Study of linvoseltamab for hard-to-treat multiple myeloma
This trial tests linvoseltamab, an experimental antibody medicine, in adults whose multiple myeloma has come back or does not respond to treatment. It may help some people by targeting myeloma cells after multiple prior therapies have failed.
Miami, FloridaAges 18 years+ - NCT03936153RecruitingPhase 2
Oral abexinostat for relapsed lymphoma after two prior treatments
This Phase 2 study tests how well and how safely an oral medicine called abexinostat works for people with diffuse large B-cell lymphoma that has come back or did not respond to the last treatment. It may help by shrinking lymphoma and controlling the disease using a medication taken by mouth.
BeijingAges 18 years+ - NCT04099966RecruitingPhase 2
Stem cell transplant to treat high-risk blood cancers
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
Valhalla, New YorkAges 1 day–30 years - NCT04162353RecruitingPhase 1
CAR cell therapy trial for multiple myeloma and related cancers
This early-phase (Phase 1) trial tests a lab-made immune-cell treatment that targets two markers, BCMA and CD19, in people whose cancer has not responded to standard options. It’s meant to see if the treatment is safe and how well it can work in these cancers.
Shenzhen, GuangdongAges Any age - NCT04211675RecruitingPhase 1/Phase 2
Test NK cell infusions with irinotecan, temozolomide, and dinutuximab
This early-phase study tests whether giving donated NK cells with three medicines can shrink neuroblastoma that has come back or not responded well to prior treatment. It’s designed for people who have limited options, and the goal is to see safety and whether the combination works.
Columbus, OhioAges Up to 29 years - NCT04318678RecruitingPhase 1
CD123 CAR T-cell therapy for relapsed leukemia and related cancers
This early-phase study tests a lab-made immune therapy (CD123 CAR T cells) for children and young adults up to age 21 whose cancer has come back or didn’t respond to treatment. The goal is to see if these CAR T cells can find and attack cancer cells that carry a marker called CD123.
Memphis, TennesseeAges Up to 21 years - NCT04421560RecruitingPhase 1/Phase 2
Testing pembrolizumab, ibrutinib, and rituximab for PCNSL
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
Boston, MassachusettsAges 18 years+ - NCT04510636RecruitingPhase 2
Pembrolizumab and bendamustine for Hodgkin lymphoma
This study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy bendamustine can help people with Hodgkin lymphoma whose cancer returned or did not respond to earlier treatment. The goal is to see if this two-drug combination works better than either drug alone.
Toronto, OntarioAges 18 years+ - NCT04544592RecruitingPhase 1/Phase 2
CD19 CAR-T for children and young adults with B-cell blood cancers
This trial tests a one-time, lab-made immune cell treatment (CD19 CAR-T) for certain B-cell blood cancers in children and young adults. It may help people whose leukemia or lymphoma is not responding to standard treatment or has come back.
Aurora, ColoradoAges 1 month–30 years - NCT04586478RecruitingPhase 2
CNCT19 cell therapy for relapsed or resistant non-Hodgkin lymphoma
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
Beijing, Beijing MunicipalityAges 18–75 - NCT04634552RecruitingPhase 2
Talquetamab study for relapsed or refractory multiple myeloma
This trial studies talquetamab, a medicine given to treat multiple myeloma that has come back or did not respond to prior treatment. It may help shrink tumors and improve disease control, depending on how your myeloma measures and your health status.
Birmingham, AlabamaAges 18 years+ - NCT04903899RecruitingPhase 2
Lutetium-DOTATATE for relapsed or hard-to-treat neuroblastoma in children
This Phase 2 trial tests a targeted radioactive medicine called 177Lutetium-DOTATATE in children with high-risk neuroblastoma that has returned or did not respond to treatment. It’s designed for tumors that show strong uptake on special scans, which may help the medicine find and treat cancer cells.
Copenhagen, CopenhagenAges 1.5 years+ - NCT04920617RecruitingPhase 2
Vaccine plus pembrolizumab, with or without low-dose chemo
This Phase 2 study tests whether a cancer vaccine called DPX-Survivac, along with pembrolizumab (an immune medicine), can help shrink diffuse large B-cell lymphoma (DLBCL) that has come back or not responded. It also looks at whether adding intermittent low-dose cyclophosphamide (a low-dose chemotherapy) improves results.
Fountain Valley, CaliforniaAges 18 years+ - NCT04929899Recruiting
Test of a learning tool during leukemia maintenance
This study checks whether a tablet-based tool (called PeNAT) can be used by children during the usual maintenance treatment phase for ALL (a type of leukemia). It may help families and clinicians better support care at home or during follow-up by testing how well the tool works in real patients.
Los Angeles, CaliforniaAges 4–18 - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Birmingham, AlabamaAges 18 years+ - NCT05650632RecruitingPhase 1
IV infusion safety study of etentamig for multiple myeloma
This is an early (Phase 1) study focused on safety of an IV medicine called etentamig in adults with relapsed or refractory multiple myeloma. It looks at how the treatment affects side effects and helps decide the safest way to give it.
Phoenix, ArizonaAges 18 years+
Hear when a new Relapsed or Refractory Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory acute myeloid leukemia (aml)?
- Yes. Clin2 currently lists 1,381 recruiting relapsed or refractory acute myeloid leukemia (aml) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory acute myeloid leukemia (aml) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory acute myeloid leukemia (aml) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Relapsed Acute Myeloid Leukemia
- Leukemia Acute Myeloid - AML
- Newly Diagnosed Acute Myeloid Leukemia (AML)
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.